Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive.~* Clinical diagnosis of Parkinson's disease.~* Able to refrain from any Parkinson's disease medication not permitted by the protocol.~Exclusion Criteria:~* Female of childbearing potential~* History or presence of atypical Parkinsonian syndrome.~* History of surgical intervention for Parkinson's disease.~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality.~* Any condition possibly affecting drug absorption.~* Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- PF-06649751 low dose (1 mg QD) (Type: EXPERIMENTAL): PF-06649751 low dose level (1 mg QD)
- PF-06649751 middle dose 1 (3 mg QD) (Type: EXPERIMENTAL): PF-06649751 lower middle dose 1 (3 mg QD)
- PF-06649751 middle dose 2 (7 mg QD) (Type: EXPERIMENTAL): PF-06649751 higher middle dose 2 (7 mg QD)
- PF-06649751 high dose (15 mg QD) (Type: EXPERIMENTAL): PF-06649751 high dose (15 mg QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).